-
10:02:00 PM

TAK Stock News

09/25/23 8:44 AM
NYSE : TAK
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Approval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of CUVITRU CUVITRU is Takeda’ s First Subcutaneous Immunoglobulin Plasma Therapy in Japan, Delivering on the Company’ s Commitment to Reach Patients with High Unmet Needs. The approval marks Takeda’ s first subcutaneous immunoglobulin...
RHEA-AI
neutral
09/20/23 8:00 AM
NYSE : TAK
clinical trial
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
Takeda today announced that the U.S. Food and Drug Administration has accepted for review its New Drug Application resubmission for TAK-721 which is being investigated for the short-term treatment of eosinophilic esophagitis, a chronic inflammatory disease that can cause damage to the esophagus. 1 The resubmission is intended...
RHEA-AI
neutral
09/13/23 10:00 AM
NYSE : TAK
partnership
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
Takeda’ s Five New Partnerships Boost Total Global CSR Program Contributions to JPY 24.2 Billion Since Program Inception in 2016. More Than 24,500 Takeda Employees Worldwide Participated in the Selection of the Five New Partnerships: Society for Family Health Rwanda, Relief International, Mercy Corps, University of Nairobi and Partners In Health. With This...
RHEA-AI
neutral
08/28/23 6:30 AM
Nasdaq, NYSE : IMGN, TAK
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan. "As a leader in the development and commercialization of novel products in oncology for more than...
RHEA-AI
positive
07/26/23 5:11 PM
NYSE : TAK
clinical trial
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development In Patients with Narcolepsy Type 1, Oral Orexin Receptor 2 Agonist Demonstrated Statistically Significant Improvement in Daytime Wakefulness; Weekly Cataplexy Rates Reduced or Abolished at All Doses Compared to Placebo Findings Indicate...
RHEA-AI
negative